Navigation Links
Study Shows MammaPrint(R) Breast Cancer Test Provides Benefits to Patients from Personalized Treatment Regimen

- New Lancet Oncology publication provides important insights on the use of

MammaPrint(R) Breast Cancer Prognosis Test in clinical practice -

AMSTERDAM, The Netherlands, Dec. 14 /PRNewswire/ -- New research demonstrates that the MammaPrint(R) breast cancer prognosis test was successfully implemented in the diagnostic process of breast cancer patients in community hospitals in The Netherlands. MammaPrint(R) assigned up to one- third of the patients to different risk categories as compared to currently used risk assessment tools. In the majority of these situations, it may lead to a reduction in the use of adjuvant chemotherapy. The findings were published in the December issue of The Lancet Oncology.

In the study, breast tumors from 585 patients with lymph node-negative, invasive breast cancer, collected at 16 hospitals in The Netherlands. Fresh samples were shipped in RNAretain(R)* at ambient temperature and were subjected at Agendia Laboratories to MammaPrint(R) gene expression analysis. Results were available for 427 patients. Based on this, patients were classified as having either a poor prognosis (high risk for distant metastasis) or good prognosis (low risk for metastasis). These results were then compared by the study coordinators to risk assessments of commonly used guidelines, including the Dutch Institute for Health Improvement (Dutch CBO) Guidelines, St. Gallen Guidelines, Nottingham Prognostic Index, and Adjuvant! Online. Many guidelines use algorithms (based on the patient's age, tumor size, and node status) to determine a patient's prognosis and determine whether or not patients should receive chemotherapy.

"More than 70 percent of patients who have node-negative breast cancer are successfully treated without chemotherapy. Identifying which patients with breast cancer will most likely require adjuvant chemotherapy is an important step in personalizing a patient's treatment regimen, and ensuring that patients aren't receiving unnecessary treatment," said Dr Laura van 't Veer, chief research officer at Agendia, who participated in the study.

According to the results in The Lancet Oncology, adjuvant chemotherapy was advised less often when the patient's prognosis was based on the DUTCH CBO Guidelines -- which are considered the most restrictive -- compared with assessments based on MammaPrint(R). For the other guidelines assessed, however, less adjuvant therapy would be given based on the prognosis of MammaPrint(R). These results confirm previous findings and validations with the test.

"These data provide important information to patients and physicians that can effectively help guide treatment decisions in community-based hospitals. The prognosis provided by MammaPrint(R), together with guidance from clinical guidelines and patients' treatment preferences, are vital tools for physicians caring for breast cancer patients," said Bernhard Sixt, chief executive officer at Agendia.

About MammaPrint(R)

MammaPrint(R) laboratory service is the first and only FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint(R) measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint(R) test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result may help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint(R) tests are conducted in Agendia's CLIA-certified central service laboratory.

About Agendia

Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test -- MammaPrint(R) -- that predicts the risk of breast cancer recurrence. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology. For more information on Agendia, please visit

* RNARetain(R) is a trademark of Asuragen Inc.

SOURCE Agendia
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... ... , ... recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
Breaking Medicine Technology: